Federal prosecutors in Manhattan are investigating a claim that Pfizer delayed announcing the success of its COVID-19 vaccine in 2020 until after that year's presidential election. The Wall Street Journal reported on this probe, citing individuals familiar with the matter.
The investigation stems from a claim brought by GSK, a rival pharmaceutical company. These allegations suggest potential misconduct related to the timing of critical public health information during a sensitive period.
This federal probe introduces significant legal and reputational risks for Pfizer. The outcome of such an investigation could have material consequences for the company, including potential fines or other penalties.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.